Location： Home > News>Industry Dynamics
On the afternoon of May 25, 2022, Taicang City held a conference on the development of innovation clusters in the biopharmaceutical industry, and the Institute of Clinical Pharmacology Technology of S
4
On June 29th, Humanwell Pharmaceutical Group Co., Ltd. announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd., had developed a Class 1 new drug, RFUS-144 injection, which ha
12
In order to guide the drug clinical trial sponsors to standardize the work related to protocol changes during clinical trials, under the deployment of the State Drug Administration, the Drug Review Ce
9
Home > News>Industry Dynamics
